Literature DB >> 17210182

Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment.

Douglas A Jabs1, Mark L Van Natta, Janet T Holbrook, John H Kempen, Curtis L Meinert, Matthew D Davis.   

Abstract

OBJECTIVE: To report the clinical features on eye examination of patients with AIDS in the era of highly active antiretroviral therapy (HAART).
DESIGN: Cohort study. PARTICIPANTS: Patients with AIDS, age > or = 13 years.
METHODS: Ophthalmologic examination, contrast sensitivity, visual fields, and laboratory testing at enrollment. MAIN OUTCOME MEASURES: Eye examination findings at enrollment.
RESULTS: As of March 31, 2003, 1632 participants with AIDS were enrolled. Evidence of intraocular inflammation was substantially more common among patients with cytomegalovirus (CMV) retinitis or other major ocular complications than among those without, as were the complications of infection and inflammation, including cataracts, pseudophakia, macular edema, and epiretinal membrane. Among patients with CMV retinitis, macular edema and epiretinal membrane formation were most common among patients with long-standing retinitis and immune recovery. Patients with newly diagnosed retinitis had eye examination findings similar to those reported in the pre-HAART era. Visual impairment (<20/40) in the better-seeing eye was present in 9.2% of patients with CMV retinitis, 41.4% of patients with other major ocular complications (primarily ocular opportunistic infections), and only 0.6% of patients with no major ocular complication (P<.0001). Although patients without major ocular complications generally had good visual acuity, approximately 9.8% of eyes and 6.6% of participants had contrast sensitivity loss sufficient to impair reading speed.
CONCLUSIONS: In the HAART era, CMV retinitis and other ocular opportunistic infections are associated with intraocular inflammation, structural ocular complications, and visual impairment. Patients with newly diagnosed CMV retinitis have eye examination findings similar to those seen in the pre-HAART era.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210182     DOI: 10.1016/j.ophtha.2006.07.065

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS.

Authors:  Efe Sezgin; Sher L Hendrickson; Douglas A Jabs; Mark L Van Natta; Richard A Lewis; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

Review 2.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

3.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

4.  Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.

Authors:  Elizabeth A Sugar; Douglas A Jabs; Alka Ahuja; Jennifer E Thorne; Ronald P Danis; Curtis L Meinert
Journal:  Am J Ophthalmol       Date:  2012-02-04       Impact factor: 5.258

5.  Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with disease-associated factors and mortality.

Authors:  Sapna Gangaputra; Partho S Kalyani; Amani A Fawzi; Mark L Van Natta; Larry D Hubbard; Ronald P Danis; Jennifer E Thorne; Gary N Holland
Journal:  Am J Ophthalmol       Date:  2011-10-22       Impact factor: 5.258

6.  Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with visual function.

Authors:  Partho S Kalyani; Amani A Fawzi; Sapna Gangaputra; Mark L van Natta; Larry D Hubbard; Ronald P Danis; Jennifer E Thorne; Gary N Holland
Journal:  Am J Ophthalmol       Date:  2011-10-22       Impact factor: 5.258

7.  Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.

Authors:  Douglas A Jabs; Alka Ahuja; Mark Van Natta; Alice Lyon; Sunil Srivastava; Sapna Gangaputra
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

8.  Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy.

Authors:  Douglas A Jabs; Mark L Van Natta; Gary N Holland; Ronald Danis
Journal:  Am J Ophthalmol       Date:  2016-10-27       Impact factor: 5.258

9.  Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome.

Authors:  Douglas A Jabs; Mark L Van Natta; Efe Sezgin; Jeong Won Pak; Ronald Danis
Journal:  Am J Ophthalmol       Date:  2015-03-11       Impact factor: 5.258

10.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.